Microbix Biosystems Inc., a biotechnology company, engages in the research, development, and commercialization of biological products and technologies worldwide. It provides cell culture based infectious disease products; and licenses cell culture based technologies, as well as is involved in the contract development work in the microbiology area. The company offers infectious disease antigens, such as viral, bacterial, and parasitic products used in various applications, including immunodiagnostic assays; basic and applied research in virology, microbiology, cell biology, molecular biology, immunology, and pathology; as controls and calibrators for a range of medical devices; and for vaccine and antiviral research and development. It also provides adenovirus vectors, cells, and services to biopharmaceutical and biotechnology researchers and companies; and water based products, such as water for injection, USP purified water, and custom solutions and buffers. In addition, the company a portfolio of biological technologies comprising LumiSort, a semen sexing technology; Urokinase, a thrombolytic drug; and VIRUSMAX, a virus yield enhancement technology. It also serves medical diagnostic and vaccine research industries. Microbix Biosystems Inc. is headquartered in Mississauga, Canada.

Key Statistics